Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
18 mars 2021 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
18 févr. 2021 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
22 janv. 2021 01h39 HE
|
Helsinn Healthcare S.A.
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media ...
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
12 janv. 2021 03h30 HE
|
Helsinn Healthcare S.A.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss...
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor
07 déc. 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor Lugano,...
Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area
01 déc. 2020 02h30 HE
|
Helsinn Healthcare S.A.
Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area Lugano, Switzerland, and Singapore,...
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)
23 sept. 2020 04h43 HE
|
Helsinn Healthcare S.A.
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI) Lugano, Switzerland,...
Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020
18 sept. 2020 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020 - A Phase 3 study concludes that a simplified regimen of...
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US
20 août 2020 09h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay
30 juil. 2020 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay Biasca, Switzerland, July 30, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare...